Showing 2621-2630 of 6036 results for "".
- Tarsus Launches Demodex Blepharitis Treatment Xdemvyhttps://modernod.com/news/tarsis-launches-demodex-blepharitis-treatment-xdemvy/2481792/Tarsus Pharmaceuticals announced that Xdemvy (lotilaner ophthalmic solution 0.25%) is now available at pharmacies nationwide for prescription. The FDA approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that w
- Penn Medicine Neuroscientists Identify Brain Mechanism that Drives Focus Despite Distractionshttps://modernod.com/news/penn-medicine-neuroscientists-identify-brain-mechanism-that-drives-focus-despite-distractions/2481770/In a new study published in Neuron, neuroscientists in the Perelman School of Medicine at the University of Pennsylvania sought to illuminate the neural mechanism that helps the brain decide whether to focus visual
- Kodiak Discontinues Further Development of Tarcocimab After Phase 3 Trial Datahttps://modernod.com/news/kodiak-discontinues-further-development-of-tarcocimab-after-phase-3-trial-data/2481748/Kodiak Sciences has announed it discontinuing further development of tarcocimab tedromer, a novel antibody biopolymer conjugate, being evaluated for wet AMD and DME. The decision comes after the GLEAM and GLIMMER studies failed to meet their primary efficacy endpoints. Th
- FDA Approves Xdemvy, First Treatment for Demodex Blepharitishttps://modernod.com/news/fda-approves-xdemvy-first-treatment-for-demodex-blepharitis/2481743/The FDA has approved Tarsus Pharmaceuticals' Xdemvy (lotilaner ophthalmic solution 0.25%) for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause
- FDA Accepts DORC’s Orphan-Drug Designation Application for Trypan Blue and Brilliant Blue Ghttps://modernod.com/news/fda-accepts-dorcs-orphan-drug-designation-application-for-trypan-blue-and-brilliant-blue-g/2481740/DORC has has received notification from the FDA that their application for orphan drug designation for a dual combination of Trypan Blue and Brilliant Blue G ophthalmic solutions has been granted. DORC's MembraneBlue-Dual ILM and ERM stain has been used in more than 500,00
- RestoringVision Appoints of Three Directors to its Leadership Teamhttps://modernod.com/news/restoringvision-appoints-of-three-directors-to-its-leadership-team/2481739/Nonprofit RestoringVision announced the appointment of three directors to its leadership team to strengthen its impact in solving the global vision crisis. This follows a year of growth, in which RestoringVision expanded its reach by 48 percent in 2022. In 2023, the organization aims to reac
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Noregen for Retinal Diseaseshttps://modernod.com/news/caeregen-therapeutics-receives-14-million-phase-2-sbir-grant-from-nihnei-to-advance-development-of-regenerative-medicine-clinical-candidate-ctr-107-noregen-for-retinal-diseases/2481729/Caeregen Therapeutics announced that it has been awarded a $1.4 million phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen), a regenerative therapeutic for the treatme
- Dean Burns Named President and CEO of Ocumeticshttps://modernod.com/news/dean-burns-named-president-and-ceo-of-ocumetics/2481722/Ocumetics Technology has appointed ophthalmic executive Dean Burns as President and CEO. Mr. Burns, whoj will also join the Ocumetics board of directors, was previously a consultant for Ocumetics, assisting with regulatory and marketing endeavours. Mr. Burns replaces 
- Nicox Presents NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis at the World Glaucoma Congresshttps://modernod.com/news/nicox-presents-ncx-470-phase-3-mont-blanc-adaptive-design-data-and-additional-subset-analysis-at-the-world-glaucoma-congress/2481705/Nicox presented additional data on NCX 470 at the 10th World Glaucoma Congress (WGC) in Rome, Italy. “The large volume of data generated in the Mont Blanc phase 3 trial on NCX 470 has provided us with the opportunity to look in detail at patient subgroups to further